An open-label, cross-over study of intramuscular (IM) and intravenous (IV) doses of SPL026 drug product (DMT fumarate [a serotonergic psychedelic]), in healthy, psychedelic-experienced subjects (Part A: IM and IV doses) and subjects with little to no psychedelic experience (Part B: IM dose only)

Cybin UK Ltd0 个研究点目标入组 14 人开始时间: 2024年2月26日最近更新: 2024年4月1日

适应症

试验速览

阶段: 1 期
状态: 已完成
发起方: Cybin UK Ltd
入组人数: 14

研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型: Interventional

入排标准

性别: All

入选标准

•Part A only:
•1. Healthy psychedelic-experienced female or male participants (psychedelic-experienced is defined as having at least two previous experiences, with breakthrough, of serotonergic psychedelic drugs, including but not limited to: DMT, ayahausca, LSD, LSA [morning glory seeds], DOI [2,5-Dimethoxy-4- iodoamphetamine], DOB [dimethoxybromoamphetamine], DOC [2,5- Dimethoxy-4-chloroamphetamine], 2CB [2-(4-bromo-2,5- dimethoxyphenyl)ethanamine], 2CE [1-(2,5-Dimethoxy-4-ethylphenyl)-2- aminoethane], mescaline, peyote, san pedro, ibogaine and psilocybin [including mushroom species containing psilocybin])
•2. No psychedelic drug use within 6 weeks prior to dosing
•Part B only:
•3. Healthy female or male participants with little to no psychedelic experience (defined as having never taken serotonergic psychedelic drugs, or have only taken sub-breakthrough doses of serotonergic psychedelic drugs, in any form, <5 times, including but not limited to: DMT, ayahuasca, LSD, LSA, DOI, DOB, DOC, 2CB, 2CE, mescaline, peyote, san pedro, ibogaine and psilocybin [including mushroom species containing psilocybin])
•4. No psychedelic drug use within 6 months prior to dosing
•Parts A and B:
•5. Aged 25-65 years
•6. A body mass index (BMI; Quetelet index) in the range 18.0-33.9 kg/m2
•7. Sufficient intelligence to understand the nature of the trial and any hazards of participating in it. Ability to communicate satisfactorily with the investigator and to participate in, and comply with the requirements of, the entire trial
•8. Willingness to give written consent to participate after reading the information and consent form, and after having the opportunity to discuss the trial with the investigator or his delegate
•9. Agree to follow the contraception requirements of the trial
•10. Agree not to donate blood or blood products during the study and for up to 3 months after the (last) administration of the trial medication
•11. Willing to refrain from psychedelic drug use (excluding the study drug) during the trial and until the follow-up call
•12. Willingness to give written consent to have data entered into the Overvolunteering Prevention System (TOPS)
•13. Willing to be contacted by email and video call, and have online access
•14. Has veins deemed suitable for cannulation (IV infusion and/or blood sampling)

排除标准

•1. Current or previously diagnosed mental health disorder as defined by the Diagnostic and Statistical Manual of Mental Disorders (DSM-V) criteria
•2. First degree relative with schizophrenia spectrum or other psychotic disorders, or bipolar and related disorders.
•3. Disposition judged by the investigator (or delegate) to be incompatible with the establishment of rapport with therapy team and/or safe exposure to DMT.
•4. Woman who is pregnant or lactating, or pre-menopausal woman who is sexually active and not using a reliable method of contraception (see section 11).
•5. Clinically relevant abnormal history, physical findings, ECG, or laboratory values at the pre-trial screening assessment that could interfere with the objectives of the trial or the safety of the participant.
•6. Presence of acute or chronic illness, condition or infection, or history of chronic illness or condition (including psychological and neurological [eg seizure] disorder) considered sufficient to invalidate the participant's participation in the trial or make it unnecessarily hazardous.
•7. Impaired endocrine, thyroid, hepatic, respiratory or renal function, diabetes mellitus, coronary heart disease or any of the following cardiovascular conditions: arrhythmia, a clinically significant screening ECG abnormality or family history of long QT syndrome or sudden death, artificial heart valve, current or any history of hypertension, or any other significant current or history of cardiovascular condition, that may affect safety in the opinion of the investigator.
•8. History of serious suicide attempts (ie those that require hospitalisation); as assessed by the BSS.
•9. Presence or history of severe adverse reaction to any drug or a history of sensitivity to serotonergic psychedelic drugs.
•10. Use of a prescription medicine (except oral contraceptives or any hormone therapy), certain herbal supplements (eg St John's Wort, to be reviewed by trial physician), or over-the-counter medicine, during the 28 days before the first dose of trial medication. Use of acetaminophen (paracetamol) and non-steroidal anti-inflammatory drugs (eg ibuprofen) is permitted up to 4 h before the first dose of trial medication.
•11. Receipt of an investigational product (including prescription medicines) as part of another clinical trial within the 3 months before (first) admission to this study; in the follow-up period of another clinical trial at the time of screening for this study.
•12. Presence or history of drug or alcohol abuse, or intake of more than 14 units of alcohol weekly.
•13. Daily cannabis use or cannabis dependence as defined by ICD10.
•14. Use of cannabis in the 24 h before each study visit.
•15. Evidence of drug abuse on urine testing (with the exception of cannabis).
•16. Unable to be nicotine-free (refrain from smoking or nicotine-containing products) for 24 h before and until the morning after dosing.
•17. Blood pressure and pulse rate in the supine and standing position at the screening examination outside the ranges: blood pressure 80-150 mm Hg systolic; 30-100 mm Hg diastolic; pulse rate 40-100 beats/min. Borderline values (i.e. values that are within 5 mm Hg of the range for blood pressure or 5 beats/min of the range for pulse rate) will be repeated. Participants can be included if the repeat value is within range or still borderline but deemed not clinically significant by the investigator.
•18. QTcF value at screening greater than 450 msec (men) or 470 msec (women) on 12-lead ECG

研究者

发起方

Cybin UK Ltd

相似试验

尚未招募

2 期

Comparison of the effectiveness of intramuscular injection of Ketorolac with PCA pump Containing Morphine and Apotel in Pain control of Patients after Cesarean SectioPainlessness after surgery.

IRCT20231005059625N1Birjand University of Medical Sciences90

招募中

3 期

To check the efficiency of two different routes (into the vein and into the muscle) of a medicine that will reduce swelling, pain and improve mouth opening after wisdom tooth removal. The medicine is dexamethasone and it reduces signs of inflammation.

CTRI/2018/10/016164Mehul Saha

尚未招募

4 期

Comparison of the effectiveness of intramuscular olanzapine with intramuscular haloperidol for the treatment of agitation in patients with Bipolar DisorderBipolar disorder.Bipolar disorder

IRCT20230131057294N1niversity of social welfare and rehabilitation sciences40

已完成

3 期

Study to Assess Safety and Efficacy of Engensis in Painful Diabetic Peripheral NeuropathyDiabetic Neuropathy, Painful

NCT04469270Helixmith Co., Ltd.162

已完成

3 期

The Effects of Intramuscular Ozone Injection in Patients with Myofascial Pain SyndromeMyofascial Pain Syndrome.Myalgia (excl. myositis)

IRCT2016042113442N10Shahid Beheshti University of Medical Sciences62